CD160 serves as a negative regulator of NKT cells in acute hepatic injury.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31332204.
- Also identified by DOI 10.1038/s41467-019-10320-y and PMC identifier 6646315.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
CD160 and BTLA both bind to herpes virus entry mediator. Although a negative regulatory function of BTLA in natural killer T (NKT) cell activation has been reported, whether CD160 is also involved is unclear. By analyzing CD160<sup>-/-</sup> mice and mixed bone marrow chimeras, we show that CD160 is not essential for NKT cell development. However, CD160<sup>-/-</sup> mice exhibit severe liver injury after in vivo challenge with α-galactosylceramide (α-GalCer). Moreover, CD160<sup>-/-</sup> mice are more susceptible to Concanavalin A challenge, and display elevated serum AST and ALT levels, hyperactivation of NKT cells, and enhanced IFN-γ, TNF, and IL-4 production. Lastly, inhibition of BTLA by anti-BTLA mAb aggravates α-GalCer-induced hepatic injury in CD160<sup>-/-</sup> mice, suggesting that both CD160 and BTLA serve as non-overlapping negative regulators of NKT cells. Our data thus implicate CD160 as a co-inhibitory receptor that delivers antigen-dependent signals in NKT cells to dampen cytokine production during early innate immune activation.
Medical subject headings
- Antigens, CD
- Chemical and Drug Induced Liver Injury
- Liver
- Natural Killer T-Cells
- Receptors, Immunologic